ArticleIranian journal of basic medical sciences2022

Development and characterization of single domain monoclonal antibody against programmed cell death ligand-1; as a cancer inhibitor candidate.

Akbar Oghalaie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.